Drug major Cipla on Thursday said it had received final nod from the US health regulator for its abbreviated new drug application (ANDA) for Tadalafil tablets 20 mg, used to treat pulmonary arterial hypertension. The firm said it had received final approval for its ANDA for Tadalafil tablets 20 mg from the United States Food and Drug Administration (USFDA). Cipla’s Tadalafil ablets 20mg is AB-rated generic therapeutic equivalent version of Eli Lilly & Co’s Adcirca.